Washington, D.C. 20549

                                    FORM 8-K

                                 Current Report
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

Date of Report (date of earliest event reported)              February 27, 2001

                                 AMERIPATH, INC.
             (Exact name of registrant as specified in its charter)


                 (State or other jurisdiction of incorporation)

              000-22313                                 65-0642485
       ------------------------              ---------------------------------
       (Commission File Number)              (IRS Employer Identification No.)

                                7289 Garden Road
                                    Suite 200
                          Riviera Beach, Florida 33404
          (Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code            (561) 845-1850


          (Former name or former address, if changed since last report)

Item 5            Other Events

On February 27, 2001, the Company held a conference call for investors and
analysts to discuss the Company's financial results for the fourth quarter and
year ended December 31, 2000. During this call, certain information was provided
regarding AmeriPath's estimated 2001 financial ratios. In order to clarify this
information, the Company is providing the following regarding the 2001

We estimate a net revenue range for the year ended December 31, 2001 of $410
million to $420 million. Our net revenue estimates are based on the annualized
fourth quarter net revenue of $370 million, same practice revenue of 12% and
limited acquisition activity. We estimate our fully diluted earnings per share
range, excluding any special charges as previously disclosed in our press
release dated February 27, 2001, to be $1.39 to $1.41. We estimate the quarterly
earnings per share, as a percentage of the annual earnings per share estimates,
to be approximately 21%, 24%, 26% and 29% for the first, second, third and
fourth quarters, respectively. We believe this is in line with analyst's current
and previous estimates.

The statements contained in this Form 8-K includes "forward-looking statements"
which are based on management's current beliefs and expectations. Past
performance is not necessarily indicative of future results. In addition,
forward-looking statements - which are identified by words such as "may",
"should", "believe", "expect", "anticipate", "estimate" and similar expressions
- as well as any financial and operating estimates, forecasts and/or
projections, are subject to a number of risks and uncertainties, many of which
involve factors or circumstances which are beyond the Company's ability to
control. These factors, risks and uncertainties could cause actual results to
differ materially from historical results or those expected, estimated or
anticipated. These include factors, risks and uncertainties relating to demand
for pathology and related services, pricing, federal and state regulation (and
compliance), reimbursement rates, government and third party payments,
dependence upon pathologists (and need to retain), key personnel and contracts,
completion and integration of acquisitions and affiliations (and achievement of
expected synergies and/or cost savings), cost and availability of financing,
competitive factors and technology. The forward looking statements included in
this Form 8-K are made as of the date hereof, and the Company undertakes no
obligation to update or revise any such statements, whether as result of new
developments, new information or otherwise. Further information regarding risks,
uncertainties and other factors that could affect the Company's financial or
operating results, or which could cause actual results to differ materially from
those expected, estimated or anticipated, are included in the Company's Form
10-K for the year ended December 31, 1999 and subsequent filings with the SEC.


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                       AMERIPATH, INC.

Dated: March 5, 2001                   By:/s/ Gregory A. Marsh
                                          Gregory A. Marsh
                                          Vice President and
                                            Chief Financial Officer